Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - AYTU BIOPHARMA, INC | v429815_ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): January 26, 2016
| AYTU BIOSCIENCE, INC. | ||
| (Exact Name of Registrant as Specified in Charter) | ||
| Delaware | 000-53121 | 47-0883144 |
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| 373 Inverness Parkway, Suite 206, Englewood, Colorado | 80112 | |
| (Address of Principal Executive Offices) | (Zip Code) | |
Registrant’s Telephone Number, Including Area Code: (720) 437-6580
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 5.02. | Departure of Directors or Certain Officers; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
Effective January 26, 2016, our Board appointed Joshua R. Disbrow and Jarrett Disbrow as directors, to hold office until our next annual meeting of stockholders.
Joshua R. Disbrow has been employed by us since April 2015. Previously, Mr. Disbrow was the Chief Executive Officer of Luoxis Diagnostics, Inc. from January 2013 to April 2015. Mr. Disbrow was also the Chief Operating Officer of Ampio Pharmaceuticals, Inc. from December 2012 to April 2015. Prior to joining Ampio, he served as the Vice President of Commercial Operations at Arbor Pharmaceuticals, a specialty pharmaceutical company, from May 2007 through October 2012. Mr. Disbrow holds an MBA from Wake Forest University and BS in Management from North Carolina State University.
Jarrett Disbrow has been employed by us since April 2015. Previously, Mr. Disbrow was the Chief Executive Officer of Vyrix Pharmaceuticals, Inc. from November 2013 to April 2015. Mr. Disbrow joined Vyrix from Eurus Pharma LLC, where he held the position of general manager from July 2011 to November 2013. Prior to joining Eurus Pharma, Mr. Disbrow was the founder, president and chief executive officer of Arbor Pharmaceuticals, Inc. from 2006 to 2010. Following Arbor Pharmaceuticals’ acquisition in 2010, Mr. Disbrow remained with the company as vice president of commercial development. Mr. Disbrow received a BS in business management from North Carolina State University.
A copy of the press release announcing the appointment of Joshua Disbrow and Jarrett Disbrow is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
| (d) | Exhibits |
| Exhibit No. | Description |
| 99.1 | Press Release dated January 27, 2016. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: January 27, 2016 | AYTU BIOSCIENCE, INC. |
| /s/ Gregory A. Gould | |
| Name: Gregory A. Gould | |
| Title: Chief Financial Officer |